ESMO 2022 Conference Coverage


 

ESMO 2022 on the Additional Practice-Informing Adverse Event Patterns and Management in the KRYSTAL-1 Phase 2 Study: Adagrasib in KRASG12Cm NSCLC

272 views
September 27, 2022
This video was recorded prior to the FDA granting approval to Adagrasib (Krazati) on December ...
read more ↘
Comments 0
Login to view comments. Click here to Login